Trial
NCT03045302
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Ipsen
Collaborators
—
Condition
Acromegaly
Intervention
BIM23B065
Why stopped
Early termination is a sponsor decision. No new safety signal or serious adverse event has been observed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-08